Research guide · Published July 22, 2026 · Sources checked July 22, 2026
BPC-157 vs TB-500-related material: what the studies actually identify
BPC-157 and Thymosin Beta-4-related materials are often grouped together, but they are different sequences. ‘TB-500’ labeling can also be ambiguous unless the exact sequence and modification state are stated.
Short answer
BPC-157 is a synthetic 15-amino-acid peptide. Full-length Thymosin Beta-4 contains 43 amino acids, while LKKTETQ is its shorter actin-binding fragment. A paper on any one of these materials is not automatically evidence for another—or for a commercial blend.
Evidence boundary: The cited preclinical findings do not establish clinical effects, a combination effect, or equivalence among differently labeled materials. Catalog materials are supplied only for qualified in vitro laboratory research and are not for human or animal use.
Comparison at a glance
| Material named | Identity in the cited research | Evidence boundary |
|---|---|---|
| BPC-157 | Synthetic 15-amino-acid peptide | Predominantly cell and animal studies |
| Thymosin Beta-4 | Full-length 43-residue peptide | Full-length findings do not automatically apply to fragments |
| LKKTETQ | Residues 17–23 actin-binding fragment | Fragment findings do not establish full-length or unspecified TB-500 behavior |
| BPC-157 + TB-500 blend | Commercial combination requiring exact identity | Ingredient papers do not establish combined behavior |
How to interpret the comparison
Sequence length, terminal modifications, counterion, and analytical identity determine whether a publication is relevant to a material. A familiar product name is insufficient.
Combination claims require direct combination research. Adding two ingredient narratives together is not evidence of synergy or safety.
Primary sources
- Chang et al., Journal of Applied Physiology (2011) — Ex vivo and in vitro tendon-fibroblast experiments involving BPC-157. DOI: 10.1152/japplphysiol.00945.2010
- Philp et al., Wound Repair and Regeneration (2003) — Mouse experiments explicitly testing full-length Thymosin Beta-4 and synthetic LKKTETQ. DOI: 10.1046/j.1524-475X.2003.11105.x
- Hsieh et al., Journal of Molecular Medicine (2017) — Endothelial-cell and animal work examining BPC-157 and VEGFR2-associated signaling. DOI: 10.1007/s00109-016-1488-y
Continue in the research library
Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.